A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)

Trial Profile

A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS)

Suspended
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Pantoprazole; Proton pump inhibitors
  • Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis; Heart failure; Myocardial infarction; NSAID-induced gastrointestinal damage; Peripheral arterial disorders; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COMPASS
  • Sponsors Bayer
  • Most Recent Events

    • 21 Aug 2017 According to a company media release, in February 2017, Janssen announced that this trial was being stopped early due to efficacy based on the recommendation of the study's independent Data Monitoring Committee (DMC), as the primary efficacy endpoint had reached its pre-specified criteria for superiority.
    • 21 Aug 2017 Status changed from active, no longer recruiting to suspended, according to a Janssen media release.
    • 21 Aug 2017 According to a Janssen media release, new data from this trial will be presented at the ESC Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top